CytoSorbents Corp., based in Princeton, New Jersey, specializes in critical care immunotherapy and blood purification technology, having launched its IPO in 2005. The company's flagship product, CytoSorb, aims to mitigate cytokine storms in severe medical conditions, alongside other products and candidates like VetResQ and DrugSorb-ATR.
CTSO has been in the news recently: CytoSorbents appointed Peter J. Mariani as CFO, effective August 14, 2024, after Kathleen P. Bloch's retirement. The company reported a 10% increase in sales, a 48% reduction in operating loss, and achieved over 250,000 CytoSorb treatments, with $9.9 million in revenue for the second quarter despite a $4.1 million loss.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
